Library Item - Page 36 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Posted by on Dec 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...

Read More

Comparing amphilimus and zotarolimus-eluting stents in patients with diabetes and coronary heart disease.

Comparing amphilimus and zotarolimus-eluting stents in patients with diabetes and coronary heart disease.

Posted by on Dec 31, 2021 in Coronary artery disease | 0 comments

In a nutshell This study compared Cre8 EVO (amphilimus-eluting) stents to Resolute Onyx (zotarolimus-eluting) stents in patients with diabetes and CAD undergoing percutaneous coronary intervention (PCI). The authors concluded that Cre8 EVO stents were similar or better than Resolute Onyx stents in these patients. Some background...

Read More

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Posted by on Dec 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review assessed the risk of hypoglycemia (dangerously low blood glucose) with the addition of sodium-glucose co-transporter 2 (SGLT-2) inhibitors to sulfonylureas in patients with type 2 diabetes (T2D). The authors concluded that this combination was associated with an increased risk of hypoglycemia. Some background...

Read More

Is AADC gene therapy a valuable option for patients with moderately advanced Parkinson Disease?

Is AADC gene therapy a valuable option for patients with moderately advanced Parkinson Disease?

Posted by on Dec 31, 2021 in Parkinson's Disease | 0 comments

In a nutshell In this work, the authors studied whether VY-AADC01 (NBIb-1817) gene therapy was safe and effective in patients with moderately advanced Parkinson's disease (PD) patients with motor fluctuations. The authors showed that this treatment caused an improvement in motor function, quality of life, and a decrease in the level of...

Read More

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva).  This study concluded that this treatment leads to an effective MRD reduction and has...

Read More

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML).  This study concluded that this treatment was safe and effective in the long-term in these...

Read More

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Posted by on Dec 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the risk of developing a range of thyroid disorders in both childhood and adult-treated female survivors of Hodgkin lymphoma (HL). The data showed that the risk of developing thyroid disorders increased significantly over time in both childhood and adult-treated survivors of HL. Some background Hodgkin lymphoma...

Read More

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Posted by on Dec 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) followed by radiofrequency ablation (RFA) for the treatment of patients with colorectal cancer liver metastasis. The data showed that NAC plus RFA improved survival outcomes in these patients. Some background Colorectal...

Read More

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Read More

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Posted by on Dec 31, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of pneumonitis (inflammation of the lung tissue) associated with immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced melanoma. The data showed that ICIs were associated with a higher risk of pneumonitis compared with conventional chemotherapy in patients with advanced melanoma. Some...

Read More

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Posted by on Dec 31, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...

Read More

Evaluating the safety and effectiveness of a four-in-one blood pressure pill early-on in patients with hypertension.

Evaluating the safety and effectiveness of a four-in-one blood pressure pill early-on in patients with hypertension.

Posted by on Dec 19, 2021 in Hypertension | 0 comments

In a nutshell This study investigated whether a single blood pressure (BP) pill containing 4 drugs (quadpill) at quarter doses is more effective than the standard dose of a single drug as initial treatment in patients with hypertension. The data showed that a quadpill was safe and more effective in getting BP under control than the standard...

Read More